
Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.
"Pfizer and Seagen have now received all required regulatory approvals," Pfizer said in a news release that reported a key US antitrust waiting period had expired. "Pfizer expects to close the acquisition of Seagen on December 14."